Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04794972 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04794972 · ClinicalTrials.gov record · last posted 2026-08-27

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1
Started2021-04-14
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.

Protocol amendment history 1 change detected by DataLookout

2026-08-28
Primary completion pushed: 2025-12 → 2026-12
Trial Details
NCT Number NCT04794972
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: SystImmune Inc.
Conditions Recurrent Glioma, Solid Tumor
Enrollment 60 participants
Start Date 2021-04-14
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-27